FoCUS Surveys Offer Insight into Payer Perspectives on Reimbursement of Expensive, One-Time Drugs

Despite concerns about the risk involved with covering high-cost durable therapies, almost all payers have opted to cover them, according to findings from a recent survey by the Financing and Reimbursement of Cures in the U.S. (FoCUS) project.

The survey, according to an article published on Pharmaceutical Executive, included input from clinical and financial health plan leaders from 77 payers between September 2018 and April 2019.

“Payers are open to multiple different approaches, although most favor short-term milestone-based contracts where therapy is paid for upfront and potential refunds are tied to failure to achieve performance metrics over the first two years following treatment,” the authors, FoCUS Project’s Jane Barlow and Matt Courtney and MIT NEWDIGS Initiative’s Mark Trusheim, write.

To read the full article on Pharmaceutical Executive, click here.